Aesica Recruits New Business Development Manager
News Jul 03, 2014
Aesica has announced the appointment of Nadine K. Reuter to the position of Business Development Manager, Finished Dose with responsibility for assisting in the drive to expand revenues from contract manufacturing activities across Germany, Austria and Switzerland.
The new role encompasses growing new business, both by working closely with existing customers and through the development of new customer relationships, in addition to raising the profile of Aesica across the region.
Based in Germany, Nadine’s primary focus consists of marketing formulation development, finished dose commercial manufacturing and packaging services to current and new customers in the countries concerned.
Prior to joining Aesica, Nadine K. Reuter worked in Germany as Head of Sales and Business Development, Life Sciences, at Esau & Hueber GmbH, a member of the Bauer Group. Prior to this, she served as Sales Manager at NNE Pharmaplan, targeting pharmaceutical and biotechnology companies in the German and Austrian regions. Earlier, she worked as a Sales Engineer in the biopharmaceuticals division of Pall Corporation focused on the Bayern and Baden Württemberg areas.
Commenting on Nadine K. Reuter’s appointment, Ian Muir, Managing Director, Finished Dose at Aesica commented: “We are delighted that Nadine has joined our European sales team and she will play an important role in driving sales and business growth in the region. We already enjoy significant business and client servicing, carried out from our German sites, located in Zwickau and Monheim, and look forward to utilizing Nadine’s sales expertise and knowledge in formulation development, finished dose manufacture and packaging, to help drive new business from existing and new customers located in the countries concerned.”
Cannabinoids Are Easier on the Brain Than Booze, Study FindsNews
The research was published in the journal Addiction.READ MORE
Compound Prevents Neurological Damage, Shows Cognitive Benefits in Mouse model of Alzheimer’s DiseaseNews
Mouse nicotinamide riboside study shows potential for human research.READ MORE